MoonLake Immunotherapeutics Investors Have Chance to Join Securities Fraud Lawsuit

Opportunity for MoonLake Investors to Lead Fraud Lawsuit

On December 8, 2025, the Law Offices of Frank R. Cruz announced an important opportunity for shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX), who have experienced financial losses. These investors may participate in a class action lawsuit concerning alleged securities fraud that directly impacts their investments. Investors are urged to act quickly, as the deadline to join the suit is December 15, 2025, just days away.

Background of the Lawsuit

The lawsuit arises from claims made against MoonLake Immunotherapeutics, particularly focusing on the period between March 10, 2024, and September 29, 2025. According to the complaint, several critical disclosures were omitted by the Company that could have influenced investors' decisions. Specifically, the allegations suggest that:

1. The Company's products, SLK and BIMZELX, share similar molecular targets—namely the inflammatory cytokines IL-17A and IL-17F, which could diminish the perceived uniqueness of SLK.
2. The Nanobody structure of SLK was promoted as having superior clinical benefits over the traditional monoclonal structure of BIMZELX, but these claims were seriously challenged.
3. SLK's purported advantage of increased tissue penetration did not translate into effective clinical outcomes, misleading investors about its efficacy.
4. Overall, the statements made by MoonLake regarding its business operations and future prospects lacked a reasonable basis, leading to a materially misleading narrative.

How to Participate in the Lawsuit

Investors who feel they have suffered losses related to their investment in MoonLake should reach out to the Law Offices of Frank R. Cruz for more information about how to join this class action lawsuit. Communication can be made via email or phone, and potential members are advised to provide details such as their mailing address and number of shares purchased to facilitate their participation.

It is essential to note that participating in this lawsuit does not require immediate action. Investors may choose their legal counsel or may remain absent members and not take any further action. The law firm stresses that the information provided may be considered attorney advertising in certain jurisdictions.

Conclusion

This class action lawsuit could serve as a critical avenue for affected investors to seek recourse against perceived wrongdoing by MoonLake Immunotherapeutics. Investors are encouraged to stay informed and act swiftly given the approaching deadline. For more details, prospective participants can visit the Law Offices' official website or contact them directly for further guidance on the process.

For ongoing updates and information, interested individuals are invited to follow the firm on Twitter. Staying proactive in such situations can be key to maximizing the potential outcomes for aggrieved parties.

Contact Information

For inquiries, the Law Offices of Frank R. Cruz can be reached at 310-914-5007 or via email at [email protected]. Further details are also available on their website at www.frankcruzlaw.com.